Jeffrey Hackman - Mar 28, 2025 Form 4/A - Amendment Insider Report for FENNEC PHARMACEUTICALS INC. (FENC)

Role
Chief Executive Officer, Director
Signature
/s/ Jeffrey Hackman
Stock symbol
FENC
Transactions as of
Mar 28, 2025
Transactions value $
$0
Form type
4/A - Amendment
Date filed
4/3/2025, 07:13 PM
Date Of Original Report
Apr 3, 2025
Previous filing
Aug 19, 2024
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction FENC Restricted Share Unit Award $0 +75K +18.75% $0.00 475K Mar 28, 2025 Common Shares 75K $0.00 Direct F1, F2
transaction FENC Stock Options Award $0 +50K +10.53% $0.00 525K Mar 28, 2025 Common Shares 50K $6.50 Direct F3, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 28, 2025, Jeffrey Hackman was awarded restricted share units to acquire 75,000 shares of the issuer's common shares pursuant to the issuer's 2020 Equity Incentive Plan
F2 One-third of the shares subject to this award shall be released from restriction as of March 28, 2026 (the "Vesting Commencement Date"). One twenty-fourth of the shares subject to this award may be released from restriction as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028 and thereafter, 100% of the total number of shares subject to this award shall be released from restriction.
F3 On March 28, 2025, Jeffrey Hackman was granted incentive stock options to purchase 50,000 shares of the issuers common shares pursuant to the Issuer's 2020 Equity Incentive Plan.
F4 One-third of the shares subject to this option may be exercised as of March 28, 2026 ("Vesting Commencement Date"). One twenty-fourth of the shares subject to this option shall vest and may be exercised as of the last day of each month following the Vesting Commencement Date. As of February 29, 2028, 100% of the total number of shares subject to this option shall be vested